News

Eisai obtained the exclusive rights to develop and market KES524 in Japan in an agreement with Abbott. Eisai had submitted a MAA for the agent to the Japanese

HGS has posted a net loss of $40.86m for the third quarter 2010, or $0.22 loss per diluted share, compared to net loss of $49m, or $0.32 loss

The agreement grants Jingxin Pharma exclusive rights to develop and market EVT 201 in China. Evotec is expected to receive a small upfront payment, together with commercial milestones

B Braun was recently notified by its supplier, Scientific Protein Laboratories LLC (SPL), that an additional testing of retained crude heparin samples used by SPL to manufacture this

Humira exerts its effects by neutralising TNF-alpha, a cytokine that plays a central role in inflammatory responses. The MHLW cleared the condition for approval on the basis of

ViroPharma has posted a net income of $38.34m for the third quarter 2010, or $0.45 per diluted share, compared to $20.07m, or $0.24 per diluted share, for the

Prior to joining Cenergy, Thomas served as COO of Engineered Sports Technology (EST), where he was successful in building relationships with raw material manufacturers as well as upper-level

Most recently, Downey was the CEO of Ketal Biomedical. Before joining Ketal, he was the president and CEO of the US and Canadian operations of Solvay Pharmaceuticals (now

AV-203 is an ErbB3 (HER3)-targeted antibody, which belongs to a family of four proteins that also includes the epidermal growth factor receptor (EGFR) and the HER2 receptor. Laureate’s